Abstract
Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Volume: 8 Issue: 1
Author(s): Giovanni D'Arena, Ronald P. Taylor, Nicola Cascavilla and Margaret A. Lindorfer
Affiliation:
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Abstract: Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Export Options
About this article
Cite this article as:
D'Arena Giovanni, Taylor P. Ronald, Cascavilla Nicola and Lindorfer A. Margaret, Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928370
DOI https://dx.doi.org/10.2174/187153008783928370 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Toll-like Receptor 2 Gene Expression in Rheumatoid Arthritis and Correlation with the Disease Activity
Current Chemical Biology An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Capillary Electrophoresis Determination of Tiopronin in Human Urine After Derivatization with 2-chloro-1-methylquinolinium Tetrafluoroborate
Current Analytical Chemistry Circumscribing the Conformational Peptide Epitope Landscape
Current Pharmaceutical Design Laboratory Biomarkers for Guiding Therapy with Methotrexate in Rheumatoid Arthritis
Current Pharmaceutical Design Cellular Mechanisms that Edit the Immunopeptidome
Current Proteomics Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Can 5-HT3 Receptor Antagonists Replace Anesthetics and Corticosteroids in the Local Treatment of Rheumatic Processes?
Current Rheumatology Reviews The Axis of Thrombospondin-1, Transforming Growth Factor Beta and Connective Tissue Growth Factor: An Emerging Therapeutic Target in Rheumatoid Arthritis
Current Vascular Pharmacology Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Anderson-Fabry Disease in Children
Current Pharmaceutical Design Structure-based Design of Mimetics for Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Current Pharmaceutical Design Ginsenosides from the Leaves and Flower Buds of Panax ginseng and their Pharmacological Effects
Current Bioactive Compounds Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Regulatory T Cells in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Metalloproteinases: potential therapeutic targets for rheumatoid arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets